Bullpen.News From Edwin Dorsey
Get Daily Recap Feedback

Sunday, November 8, 2026

Back to the front page

From X

@convequity

Convequity on X

We own both $ONTO and $CAMT because they sell overlapping tools to different HBM makers, and we raised Onto while holding Camtek. In our 4Q26 portfolio rebalance we increased Onto in our portfolio and held Camtek unchanged. Inspection identifies defects. Metrology measures dimensions and material properties to check that manufacturing meets specifications. Both companies sell inspection and metrology tools for HBM and advanced packaging, but their customer exposure differs. Onto is more closely tied to SK hynix's capital-spending plans. Our industry information identifies Camtek as a preferred supplier for Samsung's HBM production lines, and Samsung is investing aggressively to catch up with SK hynix in HBM. Camtek is smaller and more specialized, and we see a technical edge in selected HBM applications. Onto also sells chip-fabrication metrology and packaging lithography, which Camtek does not offer. We raised Onto because increasingly complex chip designs give customers reasons to keep investing beyond the current packaging recovery. We hold Camtek as the more focused advanced-packaging investment.

Investor Letters

All letters

Post Q3 EVC Update

EVC's Q3 update cites $30 million for a single station, a broadcast-business sale and stronger positioning for 2027.

EVC $832M
Nat Stewart - Stock Picking Newsletter 23 clicks

Entravision Q3 Update

Entravision’s Q3 ad-tech revenue reached $177.2 million, up 133% year over year, while total revenue rose 88% to $226.3 million and diluted…

EVC $832M
The Value Road 4 clicks
MTMTY · short

Metlen Energy & Metals PLC

Metlen Energy & Metals faces a 40% short case centered on its overpriced aluminium, alumina and Greek power businesses.

MTMTY $6.8B
Value Investors Club

GREAT DEC-TECTIVE WORK

Diversified Energy reported $255.6 million of “true” nine-month free cash flow, while its $1.8 billion Birch acquisition would shift…

DEC $900M
The Oak Bloke 3 clicks

Problems at Twist Bioscience (TWST)

Twist Bioscience’s $200 rebound followed an Anthropic-linked short squeeze, yet its DNA and protein services face broad competition while…

TWST $8B
Hunterbrook 4 clicks

VSH Earnings Review

Vishay reported record Q3 revenue of $979 million, up 24%, and guided Q4 to about $990 million as rising backlog and margins contrast with…

VSH $3.6B
Cestrian Capital Research 3 clicks

Publications we follow

Every publication on this site, hand-picked.

129 publications

Newsletters 109

YouTube 4

Blogs 15

Seeking Alpha 75 of 279

Nominate a publication

X accounts we follow

Every account on this site, hand-picked.

91 accounts
Nominate an account

Investor letters we follow

359 firms

Sectors

Ordered by how often our editor reaches for them.